Daclatasvir plus asunaprevir provided high sustained virological response rates in treatment-naive, nonresponder, and ineligible, intolerant, or ineligible and intolerant patients, and was well tolerated in patients with HCV genotype 1b infection. These results support the use of daclatasvir plus asunaprevir as an all-oral, interferon-free and ribavirin-free treatment option for patients with HCV genotype 1b infection, including those with cirrhosis. (Free registration required.)

Full Story:
The Lancet

Related Summaries